Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 1997, for Sheffield Pharmaceuticals, Inc. (formerly Sheffield Medical Technologies Inc.). The company is classified as a development stage enterprise focused on biotechnology research, licensing, and clinical trials. It has no significant product revenue and relies on external financing to fund operations. During the quarter, the company acquired Camelot Pharmacal, L.L.C., and entered into a license agreement for multi-dose inhaler (MSI) technology.
Key Financial Metrics
| Metric | Three Months Ended June 30, 1997 | Six Months Ended June 30, 1997 | Balance Sheet (June 30, 1997) |
|---|---|---|---|
| Total Revenue | $21,747 | $39,972 | N/A |
| Net Loss | $(3,421,400) | $(6,089,487) | N/A |
| Loss Per Share | $(0.29) | $(0.52) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $539,287 |
| Total Assets | N/A | N/A | $1,072,853 |
| Total Liabilities | N/A | N/A | $957,289 |
| Net Capital Deficiency | N/A | N/A | $(3,096,572) |
| Net Cash Used (Operating) | $(2,471,979) | $(4,628,933) | N/A |
Note: Revenue consists entirely of interest income. There was no sub-license revenue in the current quarter.
Material Changes vs. Prior Period
- Operating Expenses: Expenses for the three months ended June 30, 1997, were $3,443,147, a significant increase from $1,710,681 in the same period in 1996. This was primarily driven by a $1,650,000 non-cash charge for the acquisition of R&D in-process technology related to the Camelot Pharmacal acquisition.
- Liquidity: Cash and cash equivalents decreased from $1,979,871 at December 31, 1996, to $539,287 at June 30, 1997, reflecting high burn rates and a $1.1 million cash payment for the Siemens license fee.
- Capital Structure: The company issued 35,000 shares of 7% Series A Cumulative Convertible Redeemable Preferred Stock in February 1997, raising $3.5 million. Additionally, 600,000 shares of common stock were issued to acquire Camelot Pharmacal.
- Revenue: Interest income declined to $21,747 for the quarter from $52,724 in the prior year quarter due to reduced cash invested in short-term instruments.
Guidance, Outlook, and Risks
- Going Concern: Management explicitly states that the company's ability to continue as a going concern through December 1997 is dependent on obtaining additional financing. There is no assurance that such financing will be available.
- Future Funding Needs: The company projects approximately $8.3 million in additional funding requirements over the next 12 months for clinical and laboratory R&D. The largest portion ($7.5 million) is allocated to the Multi-Dose Inhaler (MSI) project.
- Strategic Initiatives:
- MSI Technology: Entered an exclusive supply and license agreement with Siemens A.G. for a pulmonary delivery system. Future payments of DM 2.0 million are due in 1998 and 1999.
- Acquisition: Completed the acquisition of Camelot Pharmacal, L.L.C., integrating its management team and technology pipeline.
- Risks: The company faces significant risks regarding the successful development and commercialization of unproven technologies, the ability to secure capital, and the potential loss of technology rights if funding is delayed.
Investor Verification Checklist
- Verify the status of ongoing financing negotiations and the likelihood of securing the projected $8.3 million in funding.
- Confirm the terms and payment schedule for the Siemens A.G. license agreement, specifically the DM 2.0 million obligations.
- Review the integration progress and technology pipeline of the newly acquired Camelot Pharmacal, L.L.C.
- Monitor cash burn rates against the current cash balance of $539,287 to assess runway before December 1997.
- Check for any updates on the commercialization timeline for the MSI and Ion Pharmaceuticals technologies.